PIPELINE – BEYOND AMI
Beyond AMI, our lead indication, Recardio is pursuing the treatment of other conditions, where dutogliptin can play a fundamental therapeutic role:
- Advanced heart failure (HF): HF is a progressive, debilitating condition that usually develops over an extended period of time as cardiac output continues to diminish. This leads to repeated decompensation events requiring hospitalization. In fact, HF is the most common cause of hospitalization in the elderly population worldwide. In the US alone, over 1 million annual events originate direct costs of more than $35 billion. Using an approach that is similar to AMI, Recardio will soon initiate the Phase 2 clinical evaluation of its combined G-CSF/dutogliptin therapy in advanced HF patients.
